Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/22731
Title: | Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests) | Authors: | Cuschieri, Kate Geraets, Daan Cuzick, Jack Cadman, Louise Moore, Catherine Vanden Broeck, Davy PADALKO, Elizaveta Quint, Wim Arbyn, Marc |
Issue Date: | 2016 | Publisher: | AMER SOC MICROBIOLOGY | Source: | JOURNAL OF CLINICAL MICROBIOLOGY, 54(9), p. 2337-2342 | Abstract: | The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an opportunity to clinically validate HPV assays for use in primary screening for cervical cancer and also provide a framework for the comparison of analytical and type-specific performance. Through VALGENT, we assessed the performance of the cartridge-based Xpert HPV assay (Xpert HPV), which detects 14 high-risk (HR) types and resolves HPV16 and HPV 18/45. Samples from women attending the United Kingdom cervical screening program enriched with cytologically abnormal samples were collated. All had been previously tested by a clinically validated standard comparator test (SCT), the GP5+/6+ enzyme immunoassay (EIA). The clinical sensitivity and specificity of the Xpert HPV for the detection of cervical intraepithelial neoplasia grade 2 or higher (CIN2+) and CIN3+ relative to those of the SCT were assessed as were the inter-and intralaboratory reproducibilities according to international criteria for test validation. Type concordance for HPV16 and HPV 18/45 between the Xpert HPV and the SCT was also analyzed. The Xpert HPV detected 94% of CIN2+ and 98% of CIN3+ lesions among all screened women and 90% of CIN2+ and 96% of CIN3+ lesions in women 30 years and older. The specificity for CIN1 or less (<= CIN1) was 83% (95% confidence interval [CI], 80 to 85%) in all women and 88% (95% CI, 86 to 91%) in women 30 years and older. Inter-and intralaboratory agreements for the Xpert HPV were 98% and 97%, respectively. The kappa agreements for HPV16 and HPV18/45 between the clinically validated reference test (GP5+/6+ LMNX) and the Xpert HPV were 0.92 and 0.91, respectively. The clinical performance and reproducibility of the Xpert HPV are comparable to those of well-established HPV assays and fulfill the criteria for use in primary cervical cancer screening. | Notes: | [Cuschieri, Kate; Moore, Catherine] Royal Infirm Edinburgh NHS Trust, Scottish HPV Reference Lab, Edinburgh, Midlothian, Scotland. [Geraets, Daan; Quint, Wim] DDL Diagnost Lab, Rijswijk, Netherlands. [Cuzick, Jack; Cadman, Louise] Wolfson Inst Prevent Med, Ctr Canc Prevent, Charterhouse Sq, London, England. [Vanden Broeck, Davy; Padalko, Elisaveta] Natl Reference Ctr HPV, Brussels, Belgium. [Vanden Broeck, Davy] Univ Ghent, Int Ctr Reprod Hlth, Ghent, Belgium. [Vanden Broeck, Davy] AML, Lab Mol Pathol, Antwerp, Belgium. [Padalko, Elisaveta] Ghent Univ Hosp, Dept Lab Med, Ghent, Belgium. [Padalko, Elisaveta] Hasselt Univ, Sch Life Sci, Diepenbeek, Belgium. [Arbyn, Marc] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium. [Arbyn, Marc] Sci Inst Publ Hlth, Belgian Canc Ctr, Brussels, Belgium. | Document URI: | http://hdl.handle.net/1942/22731 | ISSN: | 0095-1137 | e-ISSN: | 1098-660X | DOI: | 10.1128/JCM.00897-16 | ISI #: | 000384251300022 | Rights: | © 2016, American Society for Microbiology. All Rights Reserved. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2017 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Performance.pdf Restricted Access | Published version | 290.43 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
29
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
46
checked on Jul 11, 2024
Page view(s)
58
checked on Sep 7, 2022
Download(s)
46
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.